Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: macrogol 6000; lactose monohydrate; sucrose; povidone; purified talc; calcium carbonate; glycol montanate; maize starch; magnesium stearate - juliet-35 ed is indicated for: the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. juliet-35 will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis. the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. juliet-35 ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis.

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ibandronate sodium monohydrate - film-coated tablet - 150 milligram(s) - bisphosphonates; ibandronic acid

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - ibandronic acid - film-coated tablet - ibandronic acid 150 mg - drugs for treatment of bone diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: povidone; calcium carbonate; maize starch; sucrose; lactose monohydrate; macrogol 6000; purified talc; magnesium stearate; glycol montanate - diane-35 ed is indicated for: the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. diane-35 will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis.

Singapore - English - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - the baxter ak 98 dialysis machine is intended for use for hemodialysis treatments of patients with renal failure or fluid overload upon prescription by a physician. the ak 98 hemodialysis machine is indicated to be used on patients with a body weight of 25 kg or more. the ak 98 dialysis machine is intended for the in-center environment and care in a home healthcare environment. patient counseling and teaching of treatment techniques are directly under the supervision and discretion of the physician.

Australia - English - Department of Health (Therapeutic Goods Administration)

sunday supply co pty ltd - zinc oxide, quantity: 227.5 mg/g - cream - excipient ingredients: isostearic acid; coconut oil; polyglyceryl-3 polyricinoleate; d-alpha-tocopheryl acetate; medium chain triglycerides; castor oil; coco-caprylate; white beeswax - spf 50 broad spectrum high protection sunscreen

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fmc - diuron(900g/kg) - wdg - group c herbicide - asparagus | banana | barley | bore drain weed control | cereal rye | cotton | drainage ditch | irrigation channel | lupin - on l - amaranth - seedling | amsinckia | annual broadleaf weed | annual grass weed | annual grasses - see label | annual ryegrass | annual ryegrass - suppression | barley grass - seedling | barley grass - suppression | barnyard grass - seedling | broadleaf weeds - see label exceptions | brome grass - suppression | capeweed | capeweed - seedling | charlock | clover | corn gromwell, ironweed or sheepweed | deadnettle | dock - suppression | erodium spp. | fat hen - seedling | guinea grass - seedling | hedge or wild mustard | iceplant | london rocket | lupins | medic | melilotus or hexham scent | mimosa bush | mustard | mustard - seedling | perennial grasses - see label | poppy | potato or yellow weed | prickly acacia | ryegrass - seedling | saffron thistle | silver grass (v.bromoides) - suppression | sorrel - suppression | soursob or oxalis | spiny emex | summer grass - seedling | three cornered jack or doublegee | turnip | turnip weed | water weed | wild oat | wild oat - suppression | wild radish - seedling | wild rad

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm - diuron(500g/l) - suspension - group c herbicide - asparagus - pre-emergent | banana | barley | bore drain weed control | cereal rye | chickpea | cotton | drainage ditch | faba be - amaranth or amaranthus | amsinckia, yellow burrweed - seedling | amsinckia,yellow burrweed or burr grass | annual grasses - see label | annual or wimmera ryegrass | annual ryegrass - suppression | barley grass | barley grass - suppression | barnyard grass or water grass | billygoat weed or blue top | broadleaf weeds - see label exceptions | brome grass - suppression | capeweed | charlock | clover | cobbler's pegs | common iceplant | corn gromwell, ironweed or sheepweed | crassula | crowsfoot grass | deadnettle | dock - suppression | erodium spp. | erodium, crowfoot or storksbill | fat hen | guinea grass | hedge or wild mustard | iceplant | london rocket | lucerne | lupins | melilotus or hexham scent | mimosa bush | mustard | perennial grasses - see label | pigweed spp. | potato or yellow weed | prickly acacia | prince of wales feather | rough poppy | ryegrass | saffron thistle | silver grass or rat's-tail fescue | silvergrass (vulpia spp.) - suppression | sorrel - suppression | soursob or oxalis | sow or milk

Canada - English - Health Canada

mylan pharmaceuticals ulc - drospirenone; ethinyl estradiol - tablet - 3mg; 0.03mg - drospirenone 3mg; ethinyl estradiol 0.03mg - contraceptives

United States - English - NLM (National Library of Medicine)

northstar rx llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - falmina is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and norplant® system, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. emergency contraceptive pills: the fda has concluded that certain combined oral contraceptives containing ethinyl estradiol and norgestrel or levonorgestrel are safe and effective for use as postcoital emergency contraception. treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.9 lactation amenorrhea method: lam is a highly effective, temporary method of contraception.10 source: trussell j. contraceptive efficacy. in: hatcher ra, trussell j, stewart f, cates w, stewart gk, kowel d, guest f. contraceptive technology: seventeenth revised edition. new york ny: irvington publishers; 1998. 1. among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 2. among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 3. among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. 4. the proportion of women who become pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. among such populations, about 89% become pregnant within one year. this estimate was lowered slightly (to 85%) to represent the proportion who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 5. foams, creams, gels, vaginal suppositories, and vaginal film. 6. cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 7. with spermicidal cream or jelly. 8. without spermicides. 9. the treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. the fda has declared the following dosage regimens of oral contraceptives to be safe and effective for emergency contraception: for tablets containing 50 mcg of ethinyl estradiol and 500 mcg of norgestrel 1 dose is 2 tablets; for tablets containing 20 mcg of ethinyl estradiol and 100 mcg of levonorgestrel 1 dose is 5 tablets; for tablets containing 30 mcg of ethinyl estradiol and 150 mcg of levonorgestrel 1 dose is 4 tablets. 10. however, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. in a clinical trial with levonorgestrel and ethinyl estradiol tablets, 1,477 subjects had 7,720 cycles of use and a total of 5 pregnancies were reported. this represents an overall pregnancy rate of 0.84 per 100 woman-years. this rate includes patients who did not take the drug correctly. one or more pills were missed during 1,479 (18.8%) of the 7,870 cycles; thus all tablets were taken during 6,391 (81.2%) of the 7,870 cycles. of the total 7,870 cycles, a total of 150 cycles were excluded from the calculation of the pearl index due to the use of backup contraception and/or missing 3 or more consecutive pills. combination oral contraceptives should not be used in women with any of the following conditions: thrombophlebitis or thromboembolic disorders a history of deep-vein thrombophlebitis or thromboembolic disorders cerebrovascular or coronary artery disease (current or past history) valvular heart disease with thrombogenic complications thrombogenic rhythm disorders hereditary or acquired thrombophilias major surgery with prolonged immobilization diabetes with vascular involvement headaches with focal neurological symptoms uncontrolled hypertension current diagnosis of, or history of, breast cancer, which may be hormone-sensitive undiagnosed abnormal genital bleeding cholestatic jaundice of pregnancy or jaundice with prior pill use hepatic adenomas or carcinomas, or active liver disease known or suspected pregnancy hypersensitivity to any of the components of falmina women who are receiving hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alanine aminotransferase (alt) elevations (see warnings, risk of liver enzyme elevations with concomitant hepatitis c treatment ).